NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 365 filers reported holding NEKTAR THERAPEUTICS in Q1 2018. The put-call ratio across all filers is 0.43 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $2,594,000 | -85.6% | 78,915 | -73.3% | 0.57% | -75.2% |
| Q3 2018 | $18,008,000 | +52.4% | 295,405 | +22.1% | 2.30% | +26.2% |
| Q2 2018 | $11,813,000 | -5.5% | 241,922 | +105.6% | 1.82% | +144.6% |
| Q1 2018 | $12,502,000 | +947.1% | 117,662 | +488.3% | 0.75% | +584.4% |
| Q4 2017 | $1,194,000 | +84.3% | 20,000 | -60.4% | 0.11% | +289.3% |
| Q2 2014 | $648,000 | +6.6% | 50,514 | +0.7% | 0.03% | -17.6% |
| Q1 2014 | $608,000 | +10033.3% | 50,177 | +9935.4% | 0.03% | – |
| Q4 2013 | $6,000 | – | 500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |